Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sabin IPV versus Salk IPV in sequential bOPV infant immunization in Nepal
ACTRN12622000929707Phase 4Completed
- Sponsor
- World Health Organization
- Start
- Mar 2023
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of Sabin strain inactivated poliovirus vaccine in poliomyelitis (2 arms), sponsored by World Health Organization. Primary endpoint: Seroconversion against poliovirus type 2 after two IPV doses. Started Mar 2023; status: completed.
02
Drugs
Sabin strain inactivated poliovirus vaccine
03
Conditions
poliomyelitis
Beyond the preview
Go deeper on ACTRN12622000929707.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12622000929707.